Newsroom

On Wednesday, November 1, 2017, the Centers for Medicare and Medicaid Services (CMS) issued a new rule that will lower costs to taxpayers and Medicare beneficiaries for certain outpatient pharmaceuticals purchased under the 340B drug discount program.

Mark Twain once proclaimed, “The government of my country snubs honest simplicity, but fondles artistic villainy, and I think I might have developed into a very capable pickpocket if I had remained in the public service a year or two.”

My professional journey has been diverse through the years — from a senior health official with the State of California, to my current role as a Realtor here in the Desert community. But while the positions are dramatically different, the same rule applies to selling health policy as it does to selling homes: every consumer deserves an honest bill of goods.

Created in 1992 by Congress, the 340B drug discount program started with an important purpose but has recently veered off course.